U.S. Markets open in 3 hrs 39 mins

Joel Ackerman, the CEO of Champions Oncology, Inc. (CSBR), Interviews with The Wall Street Transcript

67 WALL STREET, New York - April 25, 2014 - The Wall Street Transcript has just published its Biotechnology and Pharmaceuticals Report offering a timely review of the sector to serious investors and industry executives. This special feature contains expert industry commentary through in-depth interviews with public company CEOs and Equity Analysts. The full issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.

Topics covered: Health Care - Biotechnology and Pharmaceuticals - Orphan Drug and Biologics Manufacturing - Oncology Drug Development - Orphan Drugs - FDA Approval Process - Biotechnology and Pharmaceutical Companies Valuation - Genetic and Cell Therapies

Companies include: Champions Oncology, Inc. (CSBR) and many more.

In the following excerpt from the Biotechnology and Pharmaceuticals Report, the CEO of Champions Oncology, Inc. (CSBR) discusses company strategy and the outlook for this vital industry:

TWST: Are there specific cancers that work best with these mouse avatars, or does it work with all cancers?

Mr. Ackerman: We do reasonably well with most solid tumor types. There are some, like sarcoma, where we have a particularly high demand among patients. Sarcoma, I think, is in more demand than others because it's a disease that is not well-understood. There are not a lot of great treatment options for patients. It tends to occur in patients who are younger, and they often are looking for more out-of-the-box ideas on how to personalize their care. But we've got many patients in lung cancer, in breast cancer, in pancreatic, colon and many others. We've treated 20 different tumor types over the years.

Some tumors are either too slow-growing or too small for us to really work with effectively; prostate cancer is probably the best example of that. We are looking to study some metastatic prostate cancers, but most prostate cancers are found relatively early and are very slow-growing. So that's an example of a tumor type that doesn't lend itself to the TumorGrafts model.

TWST: Where does the demand from the patient side typically come from now? Is it coming from the patient or from the doctor?

Mr. Ackerman: It comes from both. Generally, the patients who are most interested in our technology are patients who are actively engaged in the management of their own disease. They are looking for better answers. They understand how the status quo is really unlikely to deliver a great outcome for them, and they are coming to their doctor's office with information, with ideas, with questions, with suggestions. And those are the kinds of patients who ultimately find us, either through word of mouth, from their physicians or from the Web.

TWST: How often do these TumorGrafts take in a mouse? Are there some cases where it doesn't work?

For more of this interview and many others visit the Wall Street Transcript - a unique service for investors and industry researchers - providing fresh commentary and insight through verbatim interviews with CEOs, portfolio managers and research analysts. This special issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.